PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics

Pharmacogenet Genomics. 2015 Dec;25(12):622-30. doi: 10.1097/FPC.0000000000000170.

Authors

Maria L Alvarellos¹, Ellen M McDonagh, Sephalie Patel, Howard L McLeod, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Anesthesiology dMoffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, Florida, USA eGenomics England, Queen Mary University of London, London, UK.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Apnea / chemically induced
Apnea / genetics
Butyrylcholinesterase / deficiency
Butyrylcholinesterase / genetics
Calcium Channels / genetics
Calcium Channels, L-Type
Humans
Hyperkalemia / chemically induced
Hyperkalemia / genetics
Malignant Hyperthermia / etiology
Malignant Hyperthermia / genetics
Metabolism, Inborn Errors / chemically induced
Metabolism, Inborn Errors / genetics
Neuromuscular Depolarizing Agents / adverse effects
Neuromuscular Depolarizing Agents / pharmacokinetics*
Neuromuscular Depolarizing Agents / pharmacology
Pharmacogenetics
Polymorphism, Single Nucleotide / genetics
Ryanodine Receptor Calcium Release Channel / genetics
Succinylcholine / adverse effects
Succinylcholine / pharmacokinetics*
Succinylcholine / pharmacology

Substances

CACNA1S protein, human
Calcium Channels
Calcium Channels, L-Type
Neuromuscular Depolarizing Agents
Ryanodine Receptor Calcium Release Channel
Butyrylcholinesterase
Succinylcholine

Supplementary concepts

Butyrylcholinesterase deficiency

Grants and funding